Latest news
MoonLake Immunotherapeutics Announces Q2 2026 Financial Results with Increased Net Loss and Cash Reserves - Kalkine MediaKalkine Media · Mon, 10 Aug 2026 13:59:59 GMTMoonLake Immunotherapeutics Announces Q2 2026 Financial Results and Positive Phase 3 IZAR-1 Trial Data for Sonelokimab in Psoriatic Arthritis - Kalkine MediaKalkine Media · Mon, 10 Aug 2026 13:59:55 GMT